Association between CLN3 (Neuronal Ceroid Lipofuscinosis, CLN3 Type) Gene Expression and Clinical Characteristics of Breast Cancer Patients by Joelle Makoukji et al.
ORIGINAL RESEARCH
published: 12 October 2015
doi: 10.3389/fonc.2015.00215
Edited by:
Saleh AlGhamdi,
King Saud bin Abdulaziz University
For Health Sciences, Saudi Arabia
Reviewed by:
Parvin Mehdipour,
Tehran University of Medical
Sciences, Iran
Abdul-Mohsen Alhejaily,
King Fahad Medical City, Saudi Arabia
*Correspondence:
Rose-Mary Boustany,
Neurogenetics Program
and Pediatric Neurology,
Department of Pediatrics, Adolescent
Medicine and Biochemistry,
American University of Beirut,
P.O. Box 11-0236 Riad El Solh,
Beirut 1107 2020, Lebanon
rb50@aub.edu.lb
†Co-senior authors.
Specialty section:
This article was submitted to Cancer
Genetics, a section of the
journal Frontiers in Oncology
Received: 20 August 2015
Accepted: 22 September 2015
Published: 12 October 2015
Citation:
Makoukji J, Raad M, Genadry K,
El-Sitt S, Makhoul NJ, Saad Aldin E,
Nohra E, Jabbour M,
Sangaralingam A, Chelala C,
Habib RH, Boulos F, Tfayli A and
Boustany R-M (2015) Association
between CLN3 (neuronal ceroid
lipofuscinosis, CLN3 type) gene
expression and clinical characteristics
of breast cancer patients.
Front. Oncol. 5:215.
doi: 10.3389/fonc.2015.00215
Association between CLN3 (neuronal
ceroid lipofuscinosis, CLN3 type)
gene expression and clinical
characteristics of breast cancer
patients
Joelle Makoukji1, Mohamad Raad1, Katia Genadry 1, Sally El-Sitt1, Nadine J. Makhoul1,
Ehab Saad Aldin2, Eden Nohra3, Mark Jabbour 4, Ajanthah Sangaralingam5,
Claude Chelala5, Robert H. Habib6, Fouad Boulos4, Arafat Tfayli3† and
Rose-Mary Boustany 1,7†*
1 Department of Biochemistry and Molecular Genetics, American University of Beirut Medical Center, Beirut, Lebanon,
2 Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA, 3 Department of Internal Medicine,
American University of Beirut Medical Center, Beirut, Lebanon, 4 Department of Pathology and Laboratory Medicine, American
University of Beirut Medical Center, Beirut, Lebanon, 5 Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary
University of London, London, UK, 6 Outcomes Research Unit, American University of Beirut Medical Center, Beirut, Lebanon,
7 Neurogenetics Program, Division of Pediatric Neurology, Department of Pediatrics and Adolescent Medicine, American
University of Beirut Medical Center, Beirut, Lebanon
Breast cancer is the most common cancer in women worldwide. Elucidation of underlying
biology and molecular pathways is necessary for improving therapeutic options and
clinical outcomes. CLN3 protein (CLN3p), deficient in neurodegenerative CLN3 disease
is anti-apoptotic, and defects in the CLN3 gene cause accelerated apoptosis of neurons
in CLN3 disease and up-regulation of ceramide. Dysregulated apoptotic pathways are
often implicated in the development of the oncogenic phenotype. Predictably, CLN3
mRNA expression and CLN3 protein were up-regulated in a number of human and
murine breast cancer-cell lines. Here, we determine CLN3 expression in non-tumor vs.
tumor samples from fresh and formalin-fixed/paraffin-embedded (FFPE) breast tissue and
analyze the association between CLN3 overexpression and different clinicopathological
characteristics of breast cancer patients. Additionally, gene expression of 28 enzymes
involved in sphingolipid metabolism was determined. CLN3 mRNA is overexpressed in
tumor vs. non-tumor breast tissue from FFPE and fresh samples, as well as in mouse
MCF7 breast cancer compared to MCF10A normal cells. Of the clinicopathological
characteristics of tumor grade, age, menopause status, estrogen receptor, progesterone
receptor, and human epidermal growth factor receptor 2 (HER2), only absence of
HER2 expression correlated with CLN3 overexpression. Sphingolipid genes for ceramide
synthases 2 and 6 (CerS2;CerS6), delta(4)-desaturase sphingolipid 2 (DEGS2), and acidic
sphingomyelinase (SMPD1) displayed higher expression levels in breast cancer vs. control
tissue, whereas ceramide galactosyltransferase (UGT8) was underexpressed in breast
cancer samples. CLN3 may be a novel molecular target for cancer drug discovery with
the goal of modulation of ceramide pathways.
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Introduction
Globally, about 1.38 million women are diagnosed with breast
cancer and 458,503 die from the disease every year (1). The
incidence is rising in low-income and middle-income coun-
tries, a trend attributed to improved life expectancy, urban-
ization, and adoption of a Western diet and lifestyle (2–4).
In Lebanon, breast cancer is now the leading cancer among
women (5, 6) and contributes to 45% of annual registered
deaths (5). Breast cancer in Lebanon manifests larger tumor
size, more lymph node involvement, and higher tumor grades
(7, 8).
CLN3p impacts cell–cell communication, apoptosis
and autophagy, proper functioning of lysosomes, and
galactosylceramide (GalCer) lipid transport from Golgi
to lipid rafts in the plasma membrane (9). Defects in this
gene lead to Juvenile Neuronal Ceroid Lipofuscinosis or
CLN3 disease, a pediatric neurodegenerative disease (10).
In CLN3 disease, defective or low levels of CLN3p lead to
failure of GalCer transport to lipid rafts, thus impairing
lipid raft function, and resulting in toxic increases in
ceramide (9). This process leads to enhanced apoptosis of
neurons and photoreceptors initiated via caspase-8 activation
(9, 11).
Cancer and neurodegeneration are often two sides of the
same coin. Low levels of CLN3p lead to neurodegeneration and
enhanced apoptosis, and high levels of CLN3pmay lead to inhibi-
tion of apoptosis, cellular proliferation, and carcinogenesis. The
expression of CLN3 mRNA and CLN3 protein is increased in
a variety of cancers, including prostate, ovarian, colon, glioblas-
toma, and, human breast cancer-cell lines and solid colon can-
cer (Figure S1 in Supplementary Material) (12). High levels of
CLN3 are linked to inhibition of apoptosis by negatively impact-
ing ceramide generation upstream (11, 13). Moreover, block-
ing CLN3 expression using anti-sense strategies led to cancer-
cell killing, suggesting CLN3p may be a potential therapeutic
target (12).
There is increasing evidence for the involvement of sph-
ingolipid signaling in breast cancer (14). Sphingolipids are a
family of lipids lending structural support to the membrane
bilayer (15). Also, sphingolipid-regulated functions have sig-
nificant and specific links to various aspects of cancer ini-
tiation, progression, and response to anticancer treatments.
Ceramide, in particular, is intimately involved in the regu-
lation of cancer-cell growth, differentiation, senescence, and
apoptosis (16).
In this study, levels of CLN3 expression in 75 paired invasive
ductal carcinomas (IDC) and their corresponding non-tumor
freshly dissected breast tissues and another 189 breast cancer
tissue paraffin blocks and corresponding normal tissue paraffin
blocks from the same patient are compared by quantitative real-
time polymerase chain reaction (qRT-PCR). The association of
CLN3 expression with specific clinicopathological characteris-
tics of breast cancer patients is documented. In addition, gene
expression of enzymes controlling sphingolipid metabolism in
fresh-frozen breast cancer tissues is established, confirming the
CLN3-ceramide link.
Materials and Methods
Specimen Collection
A total of 75 patients with IDC of the breast were subjected to sur-
gical resection at the American University of Beirut Medical Cen-
ter, between September 2012 and May 2014. Fresh breast cancer
and corresponding non-tumor breast samples were collected and
stored in RNAlater™ (Qiagen) at  20°C. AUB-IRB (American
University of Beirut – Institutional Review Board) approved our
study (IRB number: IM.AT.05, last updated on May 27th, 2013).
Written informed consent was obtained from patients following
this AUB-IRB-approved protocol, and in accordance with the
Declaration of Helsinki. Additionally, formalin-fixed/paraffin-
embedded (FFPE) breast tissue blocks from 7 patients who under-
went reduction mammoplasty and from 189 patients (paired
IDC and their corresponding non-tumor breast tissue blocks)
were obtained from the Department of Pathology of the Amer-
ican University of Beirut Medical Center, also under an AUB-
IRB-approved protocol. All samples were used for detection of
CLN3 mRNA expression. Patient clinicopathological character-
istics were tabulated, including tumor grade, age, menopause,
estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) status.
mRNA Expression Levels
Formalin-fixed/paraffin-embedded tissue samples were cut into
20μm 10μm sections to be included per extraction. FFPE
sections were deparaffinized using xylene and lysed overnight in
proteinase K. Then, mRNA was extracted using the RiboZol™
RNA Extraction Reagent (Amresco) according to the manufac-
turer instructions. RNA was eluted in nuclease-free water and
stored at  80°C until use. RNA was treated with DNase enzyme
(Fermentas) to remove genomic DNA. Using RNeasy® Plus Mini
Kit (Qiagen), total RNA was extracted from human fresh breast
tissues, according to the manufacturer’s protocol. For assess-
ing RNA quality and yield, A260/A280 and A260/A230 ratios for
RNA were analyzed with a NanoDrop® ND-1000 spectropho-
tometer (NanoDrop Technologies) and Experion™ Automated
Electrophoresis System (BioRad), respectively.
RNA was reverse transcribed using RevertAid Reverse Tran-
scriptase (Thermo Scientific) with 100–1000 ng of input RNA
and random primers (Thermo Scientific). Quantitative real-time
PCR reactions were performed in 96-well plates using specific
primers (TIB MOLBIOL) and the iQ™ SYBR® Green Supermix
(BioRad) as a fluorescent detection dye, in CFX96™ Real-Time
PCR (BioRad), in a final volume of 12.5μl. To characterize gen-
erated amplicons and to control contamination by unspecific by-
products, melt-curve analysis is applied. Each reaction was per-
formed in duplicate. All results were normalized to PGK1mRNA
level and calculated using the ΔΔCT method. The specificity of
the PCR was determined by melt-curve analysis for each reaction.
Primer sequences are listed in Table S1 in SupplementaryMaterial
(Tm= 60°C).
Cell Culture
Human breast adenocarcinoma or MCF7 cells (ATCC) were
grown at 37°C under 5% CO2 in RPMI 1640 medium
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supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and 1%penicillin–streptomycin. Human breast epithelial or
MCF10A cells (ATCC) were maintained at 37°C in a humidified
atmosphere of 5% CO2/95% air in DMEM/F12 medium
supplemented with 5% heat-inactivated horse serum, 10μg/ml
insulin, and 100mg/ml Cholera toxin, 0.5μg/ml hydrocortisone,
20 ng/ml recombinant EGF, and 1% penicillin–streptomycin.
Mediumwas changed every 2 days, and cells were split every week.
siRNA CLN3 Knockdown
siRNA for CLN3 knockdown (BLOCK-iT RNA™Designer, Invit-
rogen) or scrambled control were transfected into MCF7 cells
(HiPerfect Transfection, Qiagen). Cell pellets are collected on
day 4 to measure ceramide levels using the diacylglycerol kinase
(DGK) assay. For validation of CLN3 knockdown, quantitative
real-time PCR reactionswere performed. Results were normalized
to Cyclophyllin A mRNA level and calculated using the ΔΔCT
method. Primer sequences are listed in Table S1 in Supplementary
Material (Tm= 60°C).
Trypan Blue Dye Exclusion Method
Cell growth and viability was determined using trypan blue dye
exclusion. About 100,000 MCF7 cells are seeded per well and
transfected with CLN3 siRNA/scrambled siRNA. After 96 h, cells
were washed, centrifuged, and fresh media added. The cells are
then stained with trypan blue dye (0.4%) and the number of white
viable and dead blue cells is counted using a light microscope and
a hemocytometer.
Propidium Iodide Staining
About 100,000 MCF7 cells are transfected with CLN3
siRNA/scrambled siRNA, suspended in 100μl PBS, incubated
with 100μl/0.5mg/ml PI, washed, placed on slides, and viewed
with a fluorescent microscope. Cells are harvested 72 and 96 h
after transfection. Three hundred cells in three different fields
of vision were counted, and percentage of red staining apoptotic
cells/total cells determined.
Measurement of Ceramide Levels
Cell Homogenization
Cell pellets were collected and washed with PBS, then suspended
in methanol/chloroform (2:1) and stored at 80°C for 48 h.
Lipid Extraction
Seven hundred microliters of distilled water are added to the
homogenate, then 1ml chloroform and 1ml of distilled water,
and the sample centrifuged for 10min at 4°C. The lower phase
is lyophilized. Lipids are resuspended in 1ml chloroform.
Ceramide Assay
Ceramide standards and samples are dried using a speed-
vac. Micelles were added to samples/standards and sonicated
for three cycles of 30min each. Reaction mixtures are added
to the ATP mix and incubated at RT for 45min. The reac-
tion is stopped using methanol/chloroform/distilled water, then
lipids extracted. These are run on a TLC plate using chloro-
form/acetone/methanol/acetic acid/water (50:20:15:10:5). Plates
are then dried, x-ray film overlaid and kept at  80°C overnight.
Ceramide bands are visualized, scraped into scintillation vials, and
counts per minute detected using a liquid scintillation counter.
The results are expressed as picomoles of ceramide per nanomole
of total phospholipids.
Phosphate Determination
After lyophilization, 150μl of 70% perchloric acid are added
to samples and to disodium hydrogen phosphate (Na2HPO4)
standards. Tubes are capped with glass balls previously soaked
in methanol and placed at 180°C for 1 h, cooled at RT and
distilled water/2.5% ammonium molybdate/10% ascorbic acid
added. Mixtures are incubated for 15min at 50°C, and concentra-
tion determined with a spectrophotometer (820 nm wavelength).
Microarray Expression Profiling and Data
Analysis
Gene expression analysis was performed on 94 fresh breast tis-
sue samples (84 cancerous and 10 normal) using the GeneChip
Human Genome U133 Plus 2.0 arrays (Affymetrix Inc.) rep-
resenting over 45,000 transcripts. Samples were prepared and
microarrays were processed using the GeneChip 30IVT Express
kit as instructed by the manufacturer. Briefly, 100 ng of total
RNA are fragmented then hybridized to the arrays. After washing
and staining using the GeneChip Fluidics Station 450, the arrays
are scanned with the GeneChip Scanner 3000 7G. Cell intensity
data (CEL) files are generated with the Affymetrix GeneChip
Command Console (AGCC) software version 3.2.
Data were analyzed within the R statistical environment
(17) using Bioconductor (http://www.bioconductor.org) pack-
ages. Stringent quality control criteria were applied to the data.
Three samples were found to be of a low quality andwere excluded
of subsequent analyses. Data were normalized jointly with the
Robust Multiarray Average (RMA) algorithm (18).
Where more than one probe was found to match the same gene
the mean expression value was calculated and used. Expression
boxplots for the genes of interest of tumor against normal samples
were generated from this expression matrix.
To detect differentially expressed genes between tumor and
normal samples, Limma (19) was used to fit a linear model
to normalized expression data for each probe. False discov-
ery rates (FDRs) were estimated using the Benjamini–Hochberg
method (20).
Statistical Analysis
CLN3 mRNA expression was quantified in breast adenocarci-
nomas and overexpression was defined as a 1.25-fold increase
in expression compared to normal tissue. Continuous data were
expressed as means SEM, whereas categorical data were sum-
marized as counts and percents. The chi-square (χ2) test for cate-
gorical variables was used to determine the association between
gene expression levels and clinicopathological characteristics.
Means of continuous data were compared by the two-tailed Stu-
dent’s t-test. For multiple group comparisons, two-way ANOVA
followed by Bonferroni’s correction was used. Gene expression
data derived by Affymetrix or real-time PCR were compared for
tumor vs. normal tissue by standard t-test. The concordance or
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discordance between normal breast tissue adjacent to the tumor
and normal breast tissue from reduction mammoplasties was
analyzed using the kappa (κ) test of concordance. Concordances
of <0.40, 0.40–0.75, and >0.75 were defined as poor, moderate,
and perfect, respectively.
SPSS statistical software version 21.0 (SPSS Inc., Chicago, IL,
USA) was used for analysis, except for the Affymetrix expres-
sion data that were analyzed using R statistical environment. All
tests were two-sided and p< 0.05 was considered as a statistically
significant difference.
Results
Patient Characteristics
Of the 189 patient malignant FFPE tissues from breast adenocar-
cinomas, only 175 had corresponding non-tumor FFPE tissue. Of
these 175 patients, 21, 49, 51, and 54 patients had Ductal Carci-
noma In Situ (DCIS), or IDC grades I, II, and III, respectively.
A total of 26 were <40 years, 56 were between 40 and 49 years,
66 were between 50 and 69 years, 22 were >70 years old. In five
patients, age was undetermined. Eighty-three were menopausal,
87 were premenopausal andmenopausal status was undetermined
in 5 patients. ER was positive in 128 patients, negative in 31.
Information on another 16 patients was not available. PR was
positive in 105, negative in 51, and undetermined in 19 patients.
Thirty-two were HER2 positive, 108 were HER2 negative and
information on an additional 35 patients was not available.
The malignant FFPE tissue from 189 patients was compared
to non-tumor FFPE tissue collected from 7 reduction mammo-
plasties. Of those, 22, 50, 57, and 60 patients had DCIS, and IDC
grades I, II, and III, respectively. A total of 29 were <40 years, 58
were between 40 and 49 years, 68 were between 50 and 69 years,
28 were >70 years old, whereas in 6 patients, age was undeter-
mined. Ninety-one were menopausal, 92 were premenopausal
and menopausal status was undetermined in 6 patients. ER was
positive in 139 and negative in 33 patients. Information on 17
patients was not available. PR was positive in 114, negative in
55 and undetermined in 20 patients. Thirty-five were HER2 pos-
itive and 117 patients were HER2 negative. Information on 37
patients was not available. Clinical characteristics of the patients
are summarized in Table 1.
Patient clinicopathological characteristics and their frequencies
from IDC of the breast and non-tumor tissue (from same patient
or from reduction mammoplasties) were compared. The table
also displays the frequency distribution and percentage of the two
variables: CLN3 overexpression and patient clinicopathological
characteristics. Statistics were calculated by the Pearson χ2 test
and undetermined samples were not included. CLN3 expression
levels were analyzed by comparing malignant tissue from breast
adenocarcinomas to corresponding non-tumor tissue. The cut-off
point forCLN3 overexpressionwas a 1.25-fold increase. A p< 0.05
was considered as statistically significant.
CLN3 Gene Expression
To determine the potential role of CLN3 in the development and
progression of IDC of the breast, 75 paired fresh tumor tissues
and 189 paired FFPE IDC breast samples were collected and
TABLE 1 | Relationship between CLN3 mRNA overexpression and patient
clinicopathological parameters of the FFPE breast carcinoma tissue.
Variable Cancer vs.
normal tissue
from
same patient
Cancer vs.
normal tissue
from reduction
mammoplasty
Number CLN3
Over-
p Number CLN3
Over-
p
expression expression
Tumor grade
DCIS 21 8 0.549 22 11 0.954
IDC grade I 49 24 50 27
IDC grade II 51 21 57 31
IDC grade III 54 19 60 30
Age (years)
<40 26 6 0.206 29 16 0.995
40–49 56 26 58 30
50–69 66 29 68 36
70+ 22 8 28 14
Undetermined 5 6
Menopause
Premenopausal 87 46 0.301 92 45 0.334
Menopausal 83 37 91 51
Undetermined 5 6
Estrogen receptor
Negative 31 12 0.845 33 16 0.429
Positive 128 52 139 73
Undetermined 16 17
Progesterone receptor
Negative 51 18 0.677 55 25 0.232
Positive 105 44 114 63 (72%)
Undetermined 19 20
HER2
Negative 108 49 0.270 117 66 0.045*
Positive 32 11 35 13
Undetermined 35 37
Patient clinicopathological characteristics and their frequency. These frequencies are used
when comparing IDC of the breast to corresponding non-tumor tissue (from same patient
or from reduction mammoplasty). The table also displays the frequency distribution and
percentage of the two variables: CLN3 overexpression and patient clinicopathological
characteristics. Statistics were calculated by the Pearson χ2 test and undetermined sam-
ples were not included. CLN3 expression levels were analyzed by comparing malignant
tissue from breast adenocarcinomas to corresponding non-tumor tissue. The cut-off point
for CLN3 overexpression was a 1.25-fold increase.
*p<0.05 was considered as statistically significant.
Italics font means statistically significant.
characterized for the relative levels of CLN3 mRNA transcripts
by qRT-PCR. When comparing FFPE IDC breast samples to the
corresponding non-tumor tissue, 38% of the DCIS cases showed
overexpression of the CLN3 gene. Overexpression of CLN3 was
highest in IDC grade I (49%). CLN3 expression was less prevalent
in IDC grade II (41%) and even less in IDC grade III (35%).
When comparing IDC breast samples to non-tumor tissue from
reduction mammoplasty patients, overexpression of CLN3 was
most prevalent for IDC grades I and II (54%), and 50% in DCIS
and also 50% in IDC grade III. There is an increase in percentages
of CLN3 overexpression when tumor tissue is compared to tissue
from reduction mammoplasties as opposed to normal tissue from
the same patient removed at surgery (Figure 1A).
Also in fresh tissue, 50% of IDC grade I cases showed overex-
pression of the CLN3 gene. Prevalence of CLN3 overexpression
is highest in IDC grade II (67%), followed by a decrease in IDC
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FIGURE 1 | Expression of CLN3 in breast adenocarcinoma samples (A) FFPE breast cancer tissue of different tumor grades (DCIS, IDC grades I, II,
and III) were collected with surrounding normal tissue and normal tissue from reduction mammoplasties. Total RNA was extracted and quantitative
real-time PCR experiments were performed using primers for the CLN3 gene. The RT-PCR was normalized using PGK1 RNA. The cut-off point for CLN3
overexpression was a 1.25-fold increase. (B) Fresh and FFPE breast tissue of different tumor grades (DCIS, IDC grades I, II, and III) were collected with surrounding
normal tissue. Total RNA was extracted and quantitative real-time PCR experiments were performed using primers for the CLN3 gene. The RT-PCR was normalized
using PGK1 RNA. The cut-off point for CLN3 overexpression was a 1.25-fold increase.
grade III (44%). Note the difference in percentages of CLN3 over-
expression in FFPE tissue (49, 41, and 35%) for IDC grades I, II,
and III, respectively. Higher percentages of CLN3 overexpression
are observed in fresh breast tissue, as compared to FFPE tissue
(Figure 1B).
CLN3 Gene Expression Levels and
Clinicopathological Characteristics
CLN3 overexpression did not correlate with lower or higher tumor
grade, age, menopausal status, ER, PR, and HER2 expression,
when comparing the level of CLN3mRNA between breast cancer
and the surrounding non-tumor tissue (Table 1).
When comparing cancerous tissue to non-tumor tissue from
reduction mammoplasties, no positive correlation was observed
with respect to CLN3 overexpression and higher tumor grades,
age, and menopause status. Similarly, there was no significant
difference inCLN3 overexpression between patients with negative
or positive ER and PR status. CLN3 overexpression in patients
with no HER2 expression was significantly higher compared to
those with positive HER2 breast cancer (p= 0.045) (Table 1). In
fact, the cross-tabulation displaying the frequency distribution
of the two variables (CLN3 mRNA expression and HER2 status)
shows that when HER2 is not expressed, CLN3 is overexpressed
in 66/117 (56%) of cases, whereas, when HER2 is overexpressed,
CLN3 is overexpressed in only 13/35 (37%) of cases (Table 1).
So, 56% of breast cancer patients that exhibit overexpression of
CLN3mRNA lack HER2 expression compared to only 37% over-
expressingHER2 (Figure S2A in SupplementaryMaterial). Fifteen
percent of those cases overexpressing CLN3 and lacking HER2
receptor are triple negative (HER2/ER/PR negative) and 85% are
ER/PR positive (Figure S2B in Supplementary Material).
Growth, Apoptosis Rate, and Ceramide Levels in
CLN3-Deficient MCF7 Cells
CLN3mRNA is overexpressed 3.5-fold inMCF7 cells compared to
MCF10A cells, making MCF7 cells an excellent in vitro model to
study the impact ofCLN3 expression in breast cancer (Figure 2A).
A significant blocking of CLN3 protein expression using CLN3
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FIGURE 2 | CLN3 expression, growth, apoptosis rate, and ceramide level in MCF7 cells. (A) Total RNA was extracted from MCF7 and MCF10A cells and
quantitative real-time PCR experiments were performed using primers for the CLN3 gene. The RT-PCR was normalized using Cyclophyllin A and the results represent
the meanSEM of at least three independent experiments. *p<0.05 by two-tailed Student’s t-test. (B) MCF7 cells were transfected with scrambled siRNA or with
siRNA directed against CLN3 (siCLN3) for 4 days. Live cells were counted in triplicates at different time points. The results represent the meanSEM of at least three
independent experiments. *p<0.05 and ****p<0.0001 by two-way ANOVA followed by Bonferroni post test. (C) Propidium iodide positive cells were counted at
different time points. The results represent the meanSEM of three independent experiments. **p<0.01 and ***p<0.001 by two-way ANOVA followed by
Bonferroni post test. (D) Ceramide levels are higher in cells transfected with siCLN3 as compared to those transfected with scrambled siRNA.
siRNA was achieved in MCF7 cells. Blocking CLN3 expression
inhibited growth and viability of MCF7 cancer cells (Figure 2B),
and increased apoptosis as shown by PI staining (Figure 2C). Pre-
vious work had shown that CLN3 negatively modulates ceramide
generation in NT2 cells that are human teratocarcinoma-derived
progenitor cells (21). Threefold higher levels of endogenous
ceramide were observed after MCF7 cells were transfected with
siRNA directed against CLN3 compared with control MCF7 cells
transfected with scrambled siRNA (Figure 2D).
Expression of Genes Involved in Sphingolipid
Metabolism
We used Affymetrix GeneChip Human Genome U133 Plus
2.0 expression arrays to determine differences in the mRNA
expression of 28 genes involved in sphingolipid metabolism
(Table S2 in Supplementary Material), in 83 cases of inva-
sive breast cancer in fresh tissue compared to 8 non-tumor
fresh breast tissue samples. Significant differences in the expres-
sion of several genes were observed in tumor samples vs.
controls. Ceramide synthase 2 (CerS2) expression was 5-fold
increased (p= 0.026), ceramide synthase 6 (CerS6) was 13.8-fold
increased (p= 0.001), delta(4)-desaturase sphingolipid 2 (DEGS2)
was 5.5-fold increased (p= 0.046), and acid sphingomyelinase
(SMPD1) was increased 1.66-fold (p= 0.013). Neuronal Ceroid
Lipofuscinosis 3 (CLN3) expression was also increased 3-fold
(p= 0.077) and ceramide galactosyltransferase (UGT8) was 19.8-
fold decreased (p= 0.064), with an adjusted p-value close to
significance (Figure 3A).
Validation of Microarray Analysis Results
with qRT-PCR
The differential expression of the six selected genes was examined
using qRT-PCR:CerS2,CerS6,DEGS2, SMPD1,CLN3, andUGT8.
Results exhibited high consistency with those of the microar-
ray analysis. Tumor status induced a significant increase in the
expression of CerS2 (p< 0.0001), CerS6 (p< 0.0001), DEGS2
(p< 0.0001), SMPD1 (p< 0.05), and CLN3 (p< 0.0001); and a
significant decrease in the expression of UGT8 (p< 0.0001) com-
pared with expression in the corresponding non-tumor tissue
(Figure 3B).
Discussion
In this study, CLN3 mRNA expression levels in breast cancer
patient FFPE and fresh tissue samples were determined and
association with patient characteristics established. The relative
overexpression of CLN3 mRNA transcripts in IDC breast FFPE
and fresh tissues was significantly higher than in surrounding
control non-tumor tissues or in control non-tumor tissue from
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FIGURE 3 | Tumor status and expression of genes of interest. (A) Box plots of six genes of interest (CerS2, CerS6, DEGS2, SMPD1, CLN3, and UGT8) coding
for enzymes involved in sphingolipid metabolism with differences in expression between normal and tumor tissue samples. The line in the middle of the boxplots
represents the median in normal and tumor samples. *p<0.05 was considered as statistically significant. (B) Relative mRNA expression was measured by RT-PCR.
The following genes related to sphingolipid metabolism are ceramide synthase 2 (CerS2), ceramide synthase 6 (CerS6), delta(4)-desaturase sphingolipid 2 (DEGS2),
acid sphingomyelinase (SMPD1), Neuronal Ceroid Lipofuscinosis 3 (CLN3), and ceramide galactosyltransferase (UGT8). Values are means of the fold changes
normalized to PGK1 mRNA expression, with their SEs represented by vertical bars. *p<0.05 by Student’s t-test (n=34).
reduction mammoplasties. Furthermore, of the six clinicopatho-
logical parameters studied (tumor grade, age, menopause status,
ER, PR, and HER2), CLN3 overexpression was significantly asso-
ciated with absence of HER2 expression (p= 0.045) in patients
with IDC of the breast (Table 2).
Receptor status is used as a guide to classify breast cancers
into four biological subtypes: (a) low grade luminal A subtype,
(b) high grade luminal B subtype (High grade, ER/PR positive or
HER2+/ER+/PR+), (c)HER2 subtype (HER2+/ER /PR ), and
(d) triple negative/basal like subtype (HER2 /ER /PR ) (22).
So, the subtypes that are negative forHER2 receptor are luminal A,
accounting for approximately 40% of all breast cancers and triple
negative/basal like tumors that represent 10–20% of breast cancers
and are negative, for all receptors. Lack of receptors limits the use
of targeted treatments, such as hormonal therapy and anti-HER-2
agents, leading to a high proportion of disease-related death. The
Human HER2 oncogene, also known as neu/c-erbB2, is respon-
sible for encoding a 185-kDa transmembrane receptor tyrosine
kinase overexpressed in 20–30%of breast cancers and is associated
with increased breast cancer recurrence and a worse progno-
sis (23). It is a member of the epidermal growth factor (EGF)
receptor (EGFR) family. The use of trastuzumab (Herceptin®),
a humanized monoclonal antibody to the HER2 extracellular
domain, improves survival in both early and metastatic HER2-
positive patients (24, 25). HER2 expression in breast cancer is
associated with poor prognosis (26). Elevated expression of the
CLN3 gene in breast cancer was significantly associated with
HER2-negativity, when comparing cancerous to non-tumor tissue
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TABLE 2 | Results comparison between cell line, FFPE, and fresh breast tissue studies.
Expression by qRT-PCR Immunocytochemistry/immunohistochemistry Western blot
Breast cancer-cell data CLN3 mRNA overexpression in tumor MCF7
cells compared to normal MCF10A cells
More intense CLN3p staining in cultured BT20 breast
cancer tumor cells compared to normal cells (12)
Overexpression
of CLN3p (12)
FFPE breast tissue CLN3 mRNA overexpression in tumor tissue
(grades I, II, and III) compared to normal tissue
Translocation of CLN3p from plasma membrane in normal
tissue to a more intense cytoplasmic CLN3 localization in
tumor tissue (Batoul Hassan Farran MS Thesis, AUB Saab
Medical Library, CLN3 expression in Breast cancer, 2010)
N/A
Fresh breast tissue CLN3 mRNA overexpression in tumor tissue
(grades I, II, and III) compared to normal tissue
N/A N/A
from reduction mammoplasties. Interestingly, only 15% of the
cases overexpressing CLN3 and lacking HER2 receptor are triple
negative (HER2/ER/PR negative) and 85% are ER/PR positive,
indicating that up-regulated CLN3 could be a good prognostic
factor in HER2-negative breast cancers, suggesting a broad appli-
cation of CLN3 targeted therapies in breast cancers that do not
overexpress HER2. To address the extent to which CLN3 could
be a prognostic factor in breast cancer, the correlation between
CLN3 expression and clinical disease outcomes, such as survival,
recurrence, and metastasis, in different subtypes of breast cancer,
would still need to be assessed.
Defects or diminished CLN3 protein expression in the juve-
nile form of CLN3 disease is associated with increased levels
of the pro-apoptotic sphingolipid ceramide in brains and cells
from these patients. Sphingolipids are bioactive lipids that play
roles in the structure and regulation of cellular membranes, and
also impact signaling acting as protagonists in neurodegenerative
disease, inflammatory disease and cancer (27). Alterations in
sphingolipid metabolism also contribute to chemoresistance and
tumor survival (28). The central character in the sphingolipid
pathway is ceramide. It is either synthesized de novo from ser-
ine and palmitate or generated by breakdown of sphingomyelin
via different sphingomyelinases (29) (Figure 4). Of the differ-
ent functions attributed to ceramide, special attention has been
given to its pro-apoptotic properties (30), and its significance as a
potential target for cancer chemotherapy (31). Previous work has
shown that CLN3 is anti-apoptotic, and that diminishing levels of
CLN3 protein in cancer cells enhances ceramide production and
results in death of cancer cells (21). Ceramide is also produced
in response to stress stimuli, including some chemotherapeutic
drugs and irradiation (16). The cell death function of ceramide
suggests that ceramide analogs may open doors to new thera-
pies to battle cancer. Thus, finding ways to increase ceramide
by exogenous treatment or by elevating endogenous ceramide in
cancer cells becomes desirable. The role of sphingolipid signaling
in HER2-negative breast cancer, however, is not yet well-defined.
We investigated whether a correlation exists between sev-
eral elements of sphingolipid metabolism and tumor status in
breast cancer in fresh tissue samples. Significant differences in
tumor vs. control non-tumor tissue in the expression of many
genes involved in this pathway were found. Ceramide synthase 2
(CerS2), ceramide synthase 6 (CerS6), delta(4)-desaturase, sphin-
golipid 2 (DEGS2), and acid sphingomyelinase (SMPD1) displayed
higher expression in tumor samples. The alteration of these four
enzymes may have several implications. First, dihydroceramide
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3-ketosphinganine
Sphinganine
Dihydroceramide
Ceramide
Sphingosine
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Transferase
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FIGURE 4 | Overview of ceramide metabolism. Substrates and
intermediates in the metabolism of ceramide are schematically shown and the
respective enzyme names are stated next to the arrows. Enzymes
overexpressed in tumor vs. normal samples are shown in green, and the ones
underexpressed are shown in red.
synthases (CerS2 andCerS6) acylate sphinganine and sphingosine
to form dihydroceramide and ceramide, respectively (Figure 4).
Erez-Roman et al. also determined that CerS2 and CerS6 mRNA
expression is higher in human breast cancer tissue compared to
paired normal tissue from the same patients (32). The hypothesis
that higher levels of dihydroceramide synthases would directly
or indirectly lead to higher levels of ceramide in tumor tissue
may be an attempt to achieve a more efficient killing of cancer
cells. The third enzyme dihydroceramide destaurase (DEGS) is
responsible for the conversion of dihydroceramides generated via
de novo biosynthesis to ceramides by the incorporation of a 4,5-
trans-double bond, a process occurring within the endoplasmic
reticulum (33) (Figure 4). The indirect augmentation of dihy-
droceramides by siRNA blockade of DEGS1 or DEGS2 decreased
cell proliferation (34). Inhibition ofDEGS1 with siRNA in human
neuroblastoma cells leads to the accumulation of endogenous
dihydroceramides with subsequent effects on cell growth, par-
ticularly cell cycle arrest (35). The enzyme acid sphingomyeli-
nase (SMase) catalyzes hydrolysis of sphingomyelin to ceramide
and phosphocholine (Figure 4). To date, four SMases have been
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identified. SMPD1 encodes lysosomal acidic SMase, and three
neutral SMases are coded for by SMPD2, SMPD3, and SMPD4,
respectively (36). Osawa et al. show that acid sphingomyelinase
(SMPD1) and ceramide levels are increased in metastatic liver
tumors of colon cancer (37). Corcoran et al. demonstrate that
neutral SMPD3 mRNA levels are increased in several tumor tis-
sues when compared with their matching normal tissues (38).
Ceramide galactosyltransferase (UGT8) showed lower expres-
sion in tumor tissue, but there is yet little information regard-
ing its impact on cancer development. UGT8 encodes an endo-
plasmic reticulum-localized enzyme responsible for synthesis
of galactosylceramide (GalCer) from ceramide (39). Altogether,
the significant differences in the expression of CerS2, CerS6,
DEGS2, SMPD1, and UGT8 sphingolipid genes in tumor tissue
go hand in hand with elevation of ceramide levels (Figure 4).
Ceramide is a well-established growth-inhibitory molecule, and
up-regulation of growth-inhibitory molecules in human malig-
nancies is not without precedence. Tumor necrosis factor-related
apoptosis-inducing ligand is up-regulated in colon cancer, and
this increase is associated with higher-grade tumors and a poorer
prognosis (40). It is more plausible that up-regulation of spe-
cific sphingolipid enzyme mRNA expression in tumors could be
a positive compensatory response by the cell as an attempt to
increase ceramide production (Figure 5).
Breast tumorigenesis is a multistep process going from benign
and atypical hyperproliferation, to in situ carcinoma, invasive
carcinomas, and culminates in metastatic disease (41). The devel-
opment and progression of breast cancer is a complex pro-
cess attributable to the interaction of many genetic, epigenetic,
and environmental factors. Altered gene expression profiles may
drive disease progression (42). Breast cancer-overexpressed gene
1 (BCOX1) mRNA transcripts are detected in breast cancer
tissues, and also, albeit at lower levels, in the corresponding
non-tumor breast tissues (43). Hence, it is possible that CLN3
may also be overexpressed in non-tumor tissue surrounding
the tumor. Discrepancy between CLN3 mRNA expression in
non-tumor tissue surrounding the tumor and non-tumor tissue
from reduction mammoplasties was calculated using the con-
cordance correlation coefficient. There was poor concordance
between non-tumor tissue surrounding the tumor and non-
tumor tissue from reduction mammoplasties (κ= 0.115) indi-
cating that CLN3 gene expression in “morphologically” nor-
mal tissue derived from breast cancer patients is different from
that of healthy individuals undergoing breast reduction surgery.
FIGURE 5 | CLN3 and sphingolipid signaling pathway interactions analyzed using Pathway Studio. Pathway Studio analysis was used to create a network
of biologically relevant genes involved in sphingolipid metabolism and CLN3 for comparisons in normal vs. tumor samples. The position of the node represents the
subcellular localization of the gene product. Lines represent type of relations that were automatically extracted from the literature. A total of five genes were
represented in the network, with a number of focus genes with functions relating to sphingolipid metabolism.
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Non-tumor breast tissue from cancer patients, although normal
at the clinical pathological level, is diseased at the molecular
level. This finding carries important clinical consequences. After
surgical removal of a tumor, there is still a high risk for tumor
to develop in the same anatomical area. The new tumor has been
traditionally explained by the growth of incompletely resected
carcinomas. For cases where the tumor had been completely
removed, according to pathology parameters, a genetically altered
field at the molecular level remains and may be the cause of
new cancer. The presence of a field with molecularly altered cells
appears to be a risk factor for cancer. So, our results confirm the
concept of field cancerization. In fact, data are widely available
that cancer can develop from genetically altered cells in a field that
was left behind in the patient after surgical removal of the initial
carcinoma (44, 45).
In clinical practice, the elucidation of the association between
gene expression profiles and clinicopathological characteristics
may aid physicians in selecting patient-suitable treatments. Our
findings confirm an association between high expression levels
of the CLN3 gene and absence of HER2 expression in breast
cancer patients, which increases the possibility of including it
as a biomarker in breast cancer diagnostics. Good biomarkers
can aid early cancer screening, confirm cancer diagnosis, predict
outcome, tailor therapy, and guide future research directions by
shedding light on new tumorigenesis pathways. The tools cur-
rently available to assess risk of progression of pre-invasive lesions
to invasive ones are largely based on epidemiological data and
patterns of progression across populations, with little guidance
regarding individual risks for tumor progression. Fonsesca et al.
show that in pre-invasive breast lesions, such as DCIS, the individ-
ual’s risk of progression to IDC is unclear, yet surgery and other
therapies seem to decrease the risk of invasive cancer (46). Also, in
prostate and colon, pre-invasive lesions are much more common
than aggressive cancers, and only 10% or less develop into invasive
ones (47). Surgical and other interventions, now considered stan-
dard of care, might be excessive in a subset of lesions not destined
to progress into aggressive phenotypes. Biomarkers can help select
patients requiring intervention, and may allow targeted strategies
to be developed for prevention of tumor progression.
A recent study demonstrated that acid ceramidase up-
regulation (a ceramide-metabolizing enzyme), is a conserved
response to radiation therapy acrossmultiple tumor types and acid
ceramidase inhibition can directly improve the clinical response to
radiotherapy in vitro and in vivo (48).
In conclusion, the expression of CLN3 is increased in human
breast cancer. Moreover, several enzymes from the de novo
ceramide synthesis pathway are differentially expressed in breast
cancer, implicating ceramide and its upstream regulator, theCLN3
gene, in breast cancer.
CLN3 expression may be an additional useful biomarker and
a novel molecular target for cancer drug discovery, the latter
achieved via modulation of ceramide pathways.
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